Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-CD19 Chimeric Antigen Receptor Modified T Cells Infusion in Mantle Cell Lymphoma

NCT02081937 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT02081937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02081937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-CD19 Chimeric Antigen Receptor Modified T Cells Infusion in Mantle Cell Lymphoma
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 31, 2014
Completion date
December 31, 2019
Enrollment
2 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic/lymphoid cancer, mantle cell lymphoma, non-hodgkin lymphoma,b cell